The US Bankruptcy Court approved the sale of substantially all of the assets of Diadexus, Inc. on July 29, 2016. The Court has authorized the Trustee to sell all of debtor's operational assets to General Atomic for a purchase price of $4.75 million in cash and in accordance with the terms and conditions that are set forth in the Purchase Agreement plus assumption of assumed liabilities. General Atomics has emerged as successful bidder at the auction. The debtor's assets include estate's right, title, and interest in and to the Debtor's operational assets. The Trustee’s return of the $0.34 million deposit to CHL is approved. The Trustee is authorized to disburse $3,000 to MyCircleHealth. General Atomics will pay $20,000 to the Landlord in satisfaction of the 'Landlord condition'.
Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.
DIADEXUS, INC. 
